<DOC>
	<DOCNO>NCT00634088</DOCNO>
	<brief_summary>The purpose study determine safety preliminary effectiveness ixabepilone plus lapatinib without capecitabine treatment human epidermal growth factor receptor 2 ( HER2 ) -positive metastatic breast cancer .</brief_summary>
	<brief_title>Phase I Study Ixabepilone Plus Lapatinib With Without Capecitabine Treatment Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Females age 18 year old histologic cytologic diagnosis adenocarcinoma originate breast Radiologic pathologic evidence cancer metastatic locally advanced ( T4 tumor stage IIIB/IIIC disease ) curable local measure , radiation surgery Positive status human epidermal growth factor receptor 2 Measurable disease per Response Evaluation Criteria In Solid Tumors guideline Karnofsky performance status 70 100 Life expectancy least 3 month Prior radiation must include 30 % major bonemarrow contain area , pelvis lumbar spine Common Terminology Criteria Grade 2 great neuropathy Inadequate hematologic , hepatic , renal function Known prior severe hypersensitivity reaction agent contain CremophorÂ® EL know hypersensitivity prior intolerance fluoropyrimidine Known suspect dihydropyrimidine dehydrogenase deficiency More 3 prior chemotherapy regimen metastatic set Prior treatment epothilone lapatinib ; prior treatment capecitabine within past 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>